Extracorporeal photopheresis for the treatment of Crohn's disease

Research output: Contribution to journalReview articlepeer-review


Colleges, School and Institutes


Small, open-label studies show promising results for ECP in the treatment of steroid-dependent and medically-refractory Crohn's disease. However, proper randomized, sham-controlled trials have not yet been performed. Based on the proposed mechanism of action of ECP, induction of a tolerogenic T cell response, ECP should be assessed in patients with early inflammatory disease rather than those who have progressed to fibrotic or stricturing disease. Randomized, sham-controlled trials need to be performed before ECP can be incorporated into standard clinical practice for the treatment of Crohn's disease.


Original languageEnglish
Pages (from-to)183-186
Number of pages4
JournalTransfusion and Apheresis Science
Issue number2
Early online date15 Feb 2015
Publication statusPublished - Apr 2015


  • Blood Component Removal, Clinical Trials as Topic, Crohn Disease, Humans, Immunosuppressive Agents, Inflammation, Photopheresis, Research Design, Steroids, T-Lymphocytes, Treatment Outcome, Journal Article, Review